bluebird bio Inc (NASDAQ:BLUE) insider David Davidson sold 4,000 shares of the stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $202.36, for a total value of $809,440.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

David Davidson also recently made the following trade(s):

  • On Monday, January 8th, David Davidson sold 3,522 shares of bluebird bio stock. The shares were sold at an average price of $173.61, for a total value of $611,454.42.
  • On Wednesday, January 3rd, David Davidson sold 6,000 shares of bluebird bio stock. The shares were sold at an average price of $180.30, for a total value of $1,081,800.00.

Shares of bluebird bio Inc (BLUE) traded down $6.60 during trading hours on Monday, hitting $192.30. The stock had a trading volume of 1,040,000 shares, compared to its average volume of 886,654. bluebird bio Inc has a 1 year low of $71.25 and a 1 year high of $222.03. The stock has a market capitalization of $8,810.00, a PE ratio of -27.43 and a beta of 2.07.

A number of equities research analysts have commented on BLUE shares. Maxim Group reiterated a “buy” rating and issued a $170.00 price target (up from $100.00) on shares of bluebird bio in a research note on Monday, October 9th. Leerink Swann reiterated an “outperform” rating and issued a $162.00 price target (up from $145.00) on shares of bluebird bio in a research note on Wednesday, November 1st. BMO Capital Markets increased their price target on bluebird bio from $134.00 to $162.00 and gave the company a “buy” rating in a research note on Monday, October 30th. Jefferies Group reiterated a “hold” rating and issued a $126.00 price target on shares of bluebird bio in a research note on Wednesday, October 11th. Finally, SunTrust Banks raised their price objective on bluebird bio from $108.00 to $163.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. bluebird bio has a consensus rating of “Hold” and a consensus target price of $161.45.

A number of hedge funds have recently made changes to their positions in the stock. American Century Companies Inc. raised its position in bluebird bio by 3.2% during the fourth quarter. American Century Companies Inc. now owns 234,220 shares of the biotechnology company’s stock valued at $41,715,000 after acquiring an additional 7,285 shares in the last quarter. Meeder Asset Management Inc. raised its position in bluebird bio by 2,110.3% during the fourth quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 612 shares in the last quarter. CIBC Asset Management Inc purchased a new position in bluebird bio during the fourth quarter valued at approximately $247,000. Aperio Group LLC raised its position in bluebird bio by 22.6% during the fourth quarter. Aperio Group LLC now owns 6,496 shares of the biotechnology company’s stock valued at $1,157,000 after acquiring an additional 1,197 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC purchased a new position in bluebird bio during the fourth quarter valued at approximately $1,225,000.

TRADEMARK VIOLATION WARNING: “Insider Selling: bluebird bio Inc (BLUE) Insider Sells 4,000 Shares of Stock” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.watchlistnews.com/insider-selling-bluebird-bio-inc-blue-insider-sells-4000-shares-of-stock/1846677.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.